The high energy demands of the postnatal mammalian heart are met primarily by ATP produced by oxidation of fatty acids in the numerous mitochondria of the differentiated cardiac myocyte. The importance of this specialized high capacity energy production system for the normal function of the adult heart is evidenced by the development of cardiomyopathy and heart failure in humans with inherited and acquired abnormalities in mitochondrial function. With aging, the heart reverts to the fetal preference for glucose oxidation over mitochondrial fatty acid oxidation, coincident with an overall decline in mitochondrial oxidative function. The contribution of these changes to the development and progression of age-related cardiovascular diseases is unknown. The recent identification of the inducible transcriptional coactivator PGC-1alpha has provided important insight into the gene regulatory mechanisms responsible for maintenance of cardiac mitochondrial oxidative capacity. Expression of PGC-1alpha is induced in heart following birth and with exercise and short-term fasting, conditions known to increase cardiac mitochondrial energy production. Forced expression of PGC-1alpha in cardiac myocytes in culture or in the hearts of transgenic mice increases mitochondrial number and stimulates respiration. Recent exciting data in rodents implicates PGC-1alpha in the known beneficial effect of caloric restriction on aging. This proposal seeks to define the role for PGC-1alpha as a critical regulatory molecule in the control of cardiac mitochondrial number and function in the developing and aging heart using loss-of-function and conditional gain-of-function strategies in genetically modified mice. Emphasis will be given to postnatal development and aging - developmental periods with significant changes in cardiac mitochondrial energy metabolism and mechanical function. The use of caloric restriction in aged mice will further assess the primary role of PGC-1alpha in promoting and maintaining the heart's abundant mitochondrial oxidative capacity and will define its link to cardiac aging.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Clinical Investigator Award (CIA) (K08)
Project #
5K08AG024844-02
Application #
6919943
Study Section
Special Emphasis Panel (ZAG1-ZIJ-6 (M1))
Program Officer
Kohanski, Ronald A
Project Start
2004-07-15
Project End
2009-06-30
Budget Start
2005-07-01
Budget End
2006-06-30
Support Year
2
Fiscal Year
2005
Total Cost
$167,512
Indirect Cost
Name
Washington University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
068552207
City
Saint Louis
State
MO
Country
United States
Zip Code
63130
Sihag, Smita; Cresci, Sharon; Li, Allie Y et al. (2009) PGC-1alpha and ERRalpha target gene downregulation is a signature of the failing human heart. J Mol Cell Cardiol 46:201-12
Lehman, John J; Boudina, Sihem; Banke, Natasha Hausler et al. (2008) The transcriptional coactivator PGC-1alpha is essential for maximal and efficient cardiac mitochondrial fatty acid oxidation and lipid homeostasis. Am J Physiol Heart Circ Physiol 295:H185-96
Leone, Teresa C; Lehman, John J; Finck, Brian N et al. (2005) PGC-1alpha deficiency causes multi-system energy metabolic derangements: muscle dysfunction, abnormal weight control and hepatic steatosis. PLoS Biol 3:e101